B2B introductions

Intronave connects FDA-regulated and commercial B2B businesses with the trusted partners, services and opportunities they need.

Independent introductions across regulated and growing markets. Building this lane in the open, 2026–.

Book a 20-minute call →
Live signal

The markets Intronave watches

Public enforcement and filing data, updated as it publishes.

FDA · Animal health

Neogen Corporation and Sciarra Aeromed each cited for CGMP and insanitary conditions, issued 09/23/2026.

FDA · Pharma

Bentley Laboratories cited for unapproved new drug, misbranding and CGMP, issued 09/17/2026.

Commercial · Capital

BioStem Technologies, Sunshine Biopharma and HCW Biologics each filed an S-1 registration on 10/02/2026.

Commercial · Digital health

VSee Health filed an S-1 registration on 10/01/2026.

Sourced from FDA warning letters and SEC EDGAR filings, September to October 2026.

How it works

No deal to point at yet, so here is exactly what Intronave puts in motion

Two introductions, one standard: every partner is vetted before anyone is introduced.

Business in motion → trusted partner

A warning letter, a recall, a new filing. When something moves, the clock starts, and Intronave puts a vetted partner or service in front of the company while it still has options.

Provider → the businesses that need them

Providers serving regulated or growing B2B companies get introduced to the ones at the moment they learn they need help.

Building in the open. Intronave is working alongside myoProcess — a vetted B2B partner trusted across $1B+ in transactions — while it routes its first introductions in this lane. The first closed match replaces this paragraph.

Work with Intronave

Where are you at, and what are you trying to fix?

Taking the first 3 counterparties in this lane.

If you are a business with a problem to fix, a partner to find or an opportunity to chase, or you serve them for a living, get in touch. The next step is a short call.

Book a 20-minute call →